Bosentan Therapy in Patients With Eisenmenger Syndrome | Zendy

Nazzareno Galiè | Zendy; Maurice Beghetti | Zendy; Michael Α. Gatzoulis | Zendy; John Granton | Zendy; Rolf M.F. Berger | Zendy; Andrea Lauer | Zendy; Eleonora Chiossi | Zendy; Michael J. Landzberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bosentan Therapy in Patients With Eisenmenger Syndrome

Author(s) -

Nazzareno Galiè,

Maurice Beghetti,

Michael Α. Gatzoulis,

John Granton,

Rolf M.F. Berger,

Andrea Lauer,

Eleonora Chiossi,

Michael J. Landzberg

Publication year - 2006

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.106.630715

Subject(s) - bosentan , medicine , endothelin receptor antagonist , cardiology , vascular resistance , sildenafil , pulmonary hypertension , placebo , anesthesia , blood pressure , endothelin receptor , alternative medicine , pathology , receptor

Eisenmenger syndrome is characterized by the development of pulmonary arterial hypertension with consequent intracardiac right-to-left shunt and hypoxemia in patients with preexisting congenital heart disease. Because Eisenmenger syndrome is associated with increased endothelin expression, patients may benefit from endothelin receptor antagonism. Theoretically, interventions that have some effect on the systemic vascular bed could worsen the shunt and increase hypoxemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research